EP4168452A4 - Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof - Google Patents
Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereofInfo
- Publication number
- EP4168452A4 EP4168452A4 EP21824799.7A EP21824799A EP4168452A4 EP 4168452 A4 EP4168452 A4 EP 4168452A4 EP 21824799 A EP21824799 A EP 21824799A EP 4168452 A4 EP4168452 A4 EP 4168452A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- immunoconjugates
- antibodies
- antibody fragments
- active anti
- conditionally active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063040913P | 2020-06-18 | 2020-06-18 | |
PCT/US2021/037400 WO2021257542A1 (en) | 2020-06-18 | 2021-06-15 | Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4168452A1 EP4168452A1 (en) | 2023-04-26 |
EP4168452A4 true EP4168452A4 (en) | 2024-07-10 |
Family
ID=79268294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21824799.7A Pending EP4168452A4 (en) | 2020-06-18 | 2021-06-15 | Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230242662A1 (en) |
EP (1) | EP4168452A4 (en) |
JP (1) | JP2023531189A (en) |
KR (1) | KR20230023800A (en) |
CN (1) | CN115702167A (en) |
AU (1) | AU2021292486A1 (en) |
CA (1) | CA3182384A1 (en) |
IL (1) | IL298902A (en) |
MX (1) | MX2022016197A (en) |
TW (1) | TW202214696A (en) |
WO (1) | WO2021257542A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016040683A1 (en) * | 2014-09-12 | 2016-03-17 | The Regents Of The University Of California | Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2810016A1 (en) * | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Novel modulators and methods of use |
WO2018089807A2 (en) * | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Anti-cd46 antibodies and methods of use |
CN109535260B (en) * | 2018-11-22 | 2021-08-10 | 东南大学 | Human chimeric antigen receptor targeting CD46 and application thereof |
-
2021
- 2021-06-15 IL IL298902A patent/IL298902A/en unknown
- 2021-06-15 KR KR1020237001966A patent/KR20230023800A/en active Search and Examination
- 2021-06-15 CN CN202180043149.6A patent/CN115702167A/en active Pending
- 2021-06-15 JP JP2022577490A patent/JP2023531189A/en active Pending
- 2021-06-15 CA CA3182384A patent/CA3182384A1/en active Pending
- 2021-06-15 US US18/002,010 patent/US20230242662A1/en active Pending
- 2021-06-15 EP EP21824799.7A patent/EP4168452A4/en active Pending
- 2021-06-15 AU AU2021292486A patent/AU2021292486A1/en active Pending
- 2021-06-15 WO PCT/US2021/037400 patent/WO2021257542A1/en active Application Filing
- 2021-06-15 MX MX2022016197A patent/MX2022016197A/en unknown
- 2021-06-18 TW TW110122286A patent/TW202214696A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016040683A1 (en) * | 2014-09-12 | 2016-03-17 | The Regents Of The University Of California | Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics |
Also Published As
Publication number | Publication date |
---|---|
CN115702167A (en) | 2023-02-14 |
KR20230023800A (en) | 2023-02-17 |
AU2021292486A1 (en) | 2023-02-09 |
MX2022016197A (en) | 2023-04-05 |
US20230242662A1 (en) | 2023-08-03 |
CA3182384A1 (en) | 2021-12-23 |
JP2023531189A (en) | 2023-07-21 |
WO2021257542A1 (en) | 2021-12-23 |
TW202214696A (en) | 2022-04-16 |
EP4168452A1 (en) | 2023-04-26 |
IL298902A (en) | 2023-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282060A (en) | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments | |
EP3753951A4 (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
IL291299A (en) | Anti-tnfr2 antibodies, composotions comprising same and uses thereof | |
ZA202206885B (en) | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof | |
IL291545A (en) | Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof | |
EP3455261A4 (en) | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof | |
ZA202004907B (en) | Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
GB202017058D0 (en) | Antibodies and uses thereof | |
EP4253414A4 (en) | Anti-tigit antibody, and pharmaceutical composition and use thereof | |
EP4081548A4 (en) | Anti-sirp? monoclonal antibodies and uses thereof | |
EP4146272A4 (en) | Covid-19 antibodies and uses thereof | |
IL288753A (en) | Conditionally active anti-epcam antibodies, antibody fragments, their immunoconjugates and uses thereof | |
EP4190819A4 (en) | Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof | |
EP4247419A4 (en) | Anti-marco antibodies and uses thereof | |
IL285953A (en) | Antibody-drug conjugates including antibody against human dlk1, and use thereof | |
EP4132569A4 (en) | Anti-phf-tau antibodies and uses thereof | |
EP3919516A4 (en) | Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
IL310535A (en) | Anti-gdf15 antibodies, compositions and uses thereof | |
IL310012A (en) | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments | |
EP4168452A4 (en) | Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof | |
IL316008A (en) | Anti-tigit-anti-pvrig bispecific antibody, pharmaceutical composition thereof and use thereof | |
IL279086A (en) | Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof | |
EP4093774A4 (en) | Conditionally active anti-her2 antibodies, antibody fragments their immunoconjugates and uses thereof | |
EP4347646A4 (en) | Anti-cd98 antibodies and uses thereof | |
EP4132952A4 (en) | Monoclonal antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230113 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20240607 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/00 20060101ALI20240604BHEP Ipc: A61P 35/00 20060101ALI20240604BHEP Ipc: A61K 51/10 20060101ALI20240604BHEP Ipc: A61K 47/68 20170101ALI20240604BHEP Ipc: C07K 16/28 20060101AFI20240604BHEP |